Search

Displaying results 2231 - 2240 of 7706 in total
  1. Drug

    rCFP-10

    go.drugbank.com/drugs/DB21907
    Approved

    rCFP-10 is a recombinant culture filtrate protein of _Mycobacterium tuberculosis_ used as an ingredient in the diagnostic agent SIILTIBCY along with [rdESAT-6].[L53638]

  2. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA. … Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection.

  3. Drug

    Metixene

    go.drugbank.com/drugs/DB00340
    Approved

    Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.

  4. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly. … Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  5. Drug

    Cyclopentamine

    go.drugbank.com/drugs/DB08999
    ApprovedWithdrawn

    It has been widely discontinued due to the safety, effectiveness, and availability of a similar drug, propylhexedrine. … Cyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia.

  6. Drug

    Folitixorin calcium

    go.drugbank.com/drugs/DB05308
    Investigational

    CoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).

  7. Drug

    Anisindione

    go.drugbank.com/drugs/DB01125
    Approved

    Anisindione is a synthetic anticoagulant and an indanedione derivative.

  8. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury. … Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties.

  9. Drug

    Arformoterol

    go.drugbank.com/drugs/DB01274
    Approved

    The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients

  10. Drug

    Insulin aspart

    go.drugbank.com/drugs/DB01306
    ApprovedInvestigational

    Marketed as the brand name product NovoRapid, insulin aspart begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. … Due to its duration of action of around 5 hours, NovoRapid is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from

    Mixtures: NOVOMIX 30 FLEXPEN INJECTION 100 u/ml, NOVOMIX 30 FLEXPEN INJECTION 100 u/mlProducts: 100 U/ML, NOVORAPID FLEXPEN INJECTION 100 u/ml